10-K: TELA Bio Reports 19% Revenue Increase in 2024, Driven by OviTex and OviTex PRS Sales

TELA Bio, Inc. announces a 19% increase in revenue for 2024, driven by growth in OviTex and OviTex PRS product sales, while reducing its net loss by 19%.

Summary

• TELA Bio, Inc. reported a 19% increase in revenue for the year ended December 31, 2024, reaching $69.3 million compared to $58.5 million in 2023.
• The revenue growth was primarily driven by increased unit sales of OviTex and OviTex PRS products.
• OviTex unit sales increased by 33%, while OviTex PRS unit sales increased by 31%.
• The company's net loss decreased by 19% to $37.8 million in 2024, compared to $46.7 million in 2023, inclusive of a $7.6 million gain from the sale of NIVIS.
• As of December 31, 2024, TELA Bio had cash and cash equivalents of $52.7 million.
• The company completed a public offering in October 2024, generating net proceeds of $42.9 million.
• TELA Bio believes its existing cash resources will be sufficient to fund operations for at least the next 12 months.
• The company is focused on expanding its customer base, driving utilization of its products, and diversifying its product offerings.
• TELA Bio is subject to risks related to achieving profitability, commercializing products, relying on third parties, protecting intellectual property, and complying with government regulations.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and reduced losses, but acknowledges ongoing risks and challenges.

Positives

• Significant revenue growth driven by increased unit sales of key products.
• Reduction in net loss demonstrates improved financial performance.
• Successful completion of a public offering strengthens the company's financial position.
• Positive clinical data supports the safety and efficacy of OviTex products.
• FDA approval for IDE application opens potential new market for OviTex PRS.
• Strategic partnerships and product diversification efforts are underway.

Negatives

• The company has incurred significant operating losses since inception and expects to incur operating losses in the future.
• The company is highly dependent on the commercial success of its OviTex products.
• The company is highly dependent on Aroa as the exclusive contract manufacturer of its OviTex and OviTex PRS products.
• The company's products and operations are subject to extensive government regulation and oversight both in the U.S. and internationally.

Risks

• The company may not be able to achieve or sustain profitability.
• The company's indebtedness may limit its flexibility in operating its business.
• The company may require substantial additional capital to finance its planned operations.
• The company may be unable to expand, manage and maintain its direct sales and marketing organizations.
• Macroeconomic conditions may negatively impact the company's business.
• Rising inflation rates could negatively impact the company's revenues and profitability.
• The company's products may become obsolete.
• The company may be unable to compete successfully with larger competitors.
• The company may be unable to renew existing or obtain additional contract positions with major group purchasing organizations and integrated delivery networks for its products.
• The company has limited data and experience regarding the safety and efficacy of certain of its products.
• The trading price of the shares of the company's common stock has been and could in the future be highly volatile.

Future Outlook

TELA Bio believes its existing cash resources will be sufficient to meet its capital requirements and fund its operations for at least the next 12 months. The company plans to continue expanding its product offerings and the treatment capabilities of its products to address a broader patient base within soft-tissue reconstruction.

Management Comments

• The company is dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements.
• The company believes that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market.

Industry Context

The medical device industry is intensely competitive and significantly affected by new product introductions and other market activities of industry participants. TELA Bio competes with larger, well-capitalized companies with greater market share and resources.

Comparison to Industry Standards

• The BRAVO study recurrence rate of 2.6% at 24 months is among the lowest reported in any published study, including those from biologic or resorbable synthetic mesh competitors.
• OviTex products are sold at prices approximately 20% to 40% lower than other biologic matrices and resorbable synthetic mesh.
• OviTex PRS products are priced below leading biologic matrices.
• Competitors in the hernia repair market include Bard (Becton, Dickinson and Company) with Phasix and Ventralight ST, and Allergan (AbbVie) with Strattice.
• Competitors in the plastic and reconstructive surgery market include Allergan (AbbVie) with AlloDerm, MTF Biologics with FlexHD, Novadaq with DermACell, RTI Surgical with Cortiva, Bard with GalaFLEX, and Integra Lifesciences with SurgiMend and DuraSorb.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to revenue growth and reduced losses.
• Employees: Continued employment and potential for career advancement due to company growth.
• Customers: Access to innovative soft-tissue reconstruction solutions.
• Suppliers: Continued business relationship with TELA Bio.
• Creditors: Increased confidence in TELA Bio's ability to repay debt due to improved financial performance.

Next Steps

• Successfully deploy the U.S. commercial organization to support growth.
• Promote awareness of products to drive surgeon use.
• Drive utilization through existing GPO and IDN contracts and secure additional contracts.
• Continue to build upon clinical evidence of the effectiveness and safety of products.
• Advance the portfolio of reinforced tissue matrices with the introduction of new product features and designs.
• Expand service offerings and diversify the supplier base to create a broader soft tissue preservation and restoration portfolio.

Key Dates

Keywords

OviTex, OviTex PRS, hernia repair, soft-tissue reconstruction, medical devices, revenue, clinical study, Aroa, FDA, profitability